NCT00221312

Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss

Alendronate to Prevent Perimenopausal Transition Bone Loss

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 48 (actual)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: Female
• Age: 40 Years – 54 Years
• Healthy volunteers: Accepted

Summary

This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate of bone loss which often begins to increase in the three to five years preceding the menopause (perimenopausal transition). During the three to five years prior to the menopause, the rate of bone loss increases. One way that physicians treat this is with oral contraceptive medication. However, the incidence of complications from oral contraceptives after the age of 40 increases. Therefore, a non-hormonal means of preventing bone loss should be useful. Fosamax (alendronate) is in a class of compounds called bisphosphonates. This study is being done to determine whether Fosamax can be used to prevent the increased rate of bone loss during the perimenopausal transition.

Conditions

• Perimenopausal Bone Loss

Interventions

Type	Name	Description
DRUG	Fosamax

Timeline

• Start date: 2002-05-01
• Completion: 2007-07-01
• First posted: 2005-09-22
• Last updated: 2008-05-08

Locations

1 site across 1 country: United States